Categories
Blood Cancer

Exciting treatment combinations emerging in myeloma [Video]

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses current and upcoming treatment combinations in multiple myeloma, drawing focus on immunotherapies. Dr Costa first highlights the promise of CAR-T therapy, and then goes on to discuss bispecific T-cell engagers (BiTEs). Other promising approaches in this field include monoclonal antibodies, and Dr Costa highlights some clinical trials investigating the earlier use of these agents, such as the MajesTEC-1 (NCT04557098) and MagnetisMM-3 (NCT04649359) trials. To conclude, Dr Costa discusses the role of BCL2 inhibitors and their place in the myeloma treatment landscape. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

Current and future implications of MRD in myeloma [Video]

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the current and future implications of measurable residual disease (MRD) in multiple myeloma. Dr Costa first highlights the importance of MRD as a powerful prognostic tool, and further discusses how it can be used to identify patients at high risk of relapse. Following this, Dr Costa discusses some ongoing and future clinical trials incorporating MRD, including the AURIGA trial (NCT03901963), the MIDAS trial (NCT04934475), and the upcoming MASTER-2 trial (NCT05231629). This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

Lymphoma highlights from ASH 2021 [Video]

Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, comments on his highlights in the field of lymphoma presented at ASH 2021, including the Phase III POLARIX trial (NCT03274492) of polatuzumab vedotin (R-CHP) in diffuse large B-cell lymphoma (DLBCL). Dr Mehta additionally talks on the ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), BELINDA (NCT03570892), and ELARA (NCT03568461) trials, which all assessed chimeric antigen receptor (CAR) T-cell therapies, as well as bispecific antibodies such as glofitamab and mosunetuzumab. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Real world use of CAR T-cell therapy in multiple myeloma [Video]

Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma who have undergone 4 or more prior therapies. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the number of patients who are able to receive ide-cel. Data from the Flatiron Health Electronic Health Record (EHR) suggests fewer than 15% of patients are eligible for treatment, with a number of patients dying before being eligible. Dr Costa thus highlights the need to approve CAR T-cell therapies for earlier lines of treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

MASTER: Dara-KRd in patients with multiple myeloma [Video]

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses findings from the Phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) followed by autologous transplantation in patients with newly diagnosed multiple myeloma (MM). Patients additionally received Dara-KRd consolidation based on minimal residual disease (MRD) status, with the primary endpoint being MRD negativity. A majority of the cohort achieved a complete response and MRD negativity, but progression-free survival was lower in patients with ultra-high risk MM. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.